Distribution of Aminoglycoside Resistance Genes Among
Acinetobacter baumannii Strains Isolated From Burn Patients in
Tehran, Iran

Saeed Khoshnood,1,2 Gita Eslami,1,2,7 Ali Hashemi,1 Aghil Bahramian,1 Mohsen Heidary,3 Neda Yousefi,1
Fariba Mohammadi,1 and Mehrdad Gholami3

1Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
3Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, IR Iran

1Corresponding author: Gita Eslami, Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, P. Box: 19857-17443, Tehran, IR Iran. Tel: +98-2121925556, E-mail: g_eslami@yahoo.com

Received 2016 July 29; Revised 2017 January 02; Accepted 2017 January 17.

Abstract

Background: Acinetobacter baumannii is an important cause of nosocomial infections, particularly in burn patients. Hospital Infections caused by these bacteria are difficult to treat.

Objectives: The present study aimed at determining the frequency of genes encoding aminoglycoside-modifying enzymes in A. baumannii strains isolated from burn patients in Shahid Motahari hospital.

Methods: This study was performed on 100 A. baumannii strains collected from Shahid Motahari hospital in Tehran during 2013 and 2014. The bacteria were cultured and identified. Antibiotic susceptibility testing was performed by disk diffusion method according to the CLSI guidelines. PCR assay was done to find the genes encoding aminoglycoside-modifying enzymes.

Results: In this study, highest resistance to antibiotic was reported for ceftriaxone, ciprofloxacin, and ceftizoxime (100%), whereas the highest susceptibility was observed for colistin (100%), followed by gentamicin, amikacin, and tobramycin with (93%), (90%), and (87%), respectively. In the total of 100 strains studied, aphA6, aadB, aacC1 and aadA1 genes were found in 65, 221, and 37 of A. baumannii isolates, respectively; 8 isolates had aadB and aphA6 genes and 3 had aadB, aadA1, aacC1, and aphA6 genes.

Conclusions: This study showed the high frequency aminoglycoside-resistance genes among A. baumannii strains. Thus, the implementation of appropriate programs to prevent the spread of the bacteria seems necessary in the Shahid Motahari hospital.

Keywords: Aminoglycoside Resistance Genes, Multidrug Resistance, Burn, Acinetobacter baumannii

1. Background

Burns are one of the most common forms of trauma. Burn patients have an urgent need of specialized services to minimize the effects of mortality; 75% of all deaths in patients with severe burns over 40% are due to infection caused by burns. In burn patients, normal function of the skin and immune response is impaired (1). Burn wounds are a suitable environment for the growth of different species of bacteria and factors such as age, depth and extent of the burn can affect these infections (2). Acinetobacter baumannii is a gram-negative cocobacilli bacterium broadly accessible in water and soil and stays alive for long periods in hospitals and is easily passed from person to person.

Due to the drug-resistant strains in the world, Acinetobacter baumannii is now one of the nosocomial pathogens, particularly in burn patients and in those in intensive care units. A. baumannii causes various infections such as endocarditis, peritonitis, respiratory tract infections, meningitis, burns, and sepsis in different parts of the hospital (1, 2). Nowadays, due to the indiscriminate and unnecessary use of broad-spectrum antibiotics, A. baumannii has become resistant to a wide range of antibiotics.

Over the past decade, this bacterium has been considered as one of the most troublemaking pathogens and its treatment has been limited to a few antibiotics. Studies have shown that A. baumannii has innate and adaptive resistance to many antibiotics including beta-lactams, aminoglycosides, fluoroquinolons, and carbapenems (3-6). The fast development and worldwide dissemination of A. baumannii as a major nosocomial pathogen is significant and shows its successful adaptation to the 21st century hospital wards (7). The 2 main mechanisms of resistance to aminoglycosides are as follow: first, changes in the structure of the ribosome as a result of the structural protein mutant ribosomes, rRNA or enzymatically; and the second, changes in the structure of antibiotics by enzymes (8).
most common mechanism of resistance to aminoglycosides in this bacterium is the modification of hydroxyl or amino groups of the antibiotic by modifying aminoglycoside (9, 10), albeit other mechanisms such as reduced permeability and change of the binding sites have been suggested (11). Aminoglycosides have long been used for the therapy of infection in hospitalized patients and still are an essential option for treatment of diseases created by MDR strains. MDR A. baumannii was characterized as the strain having acquired nonsusceptibility to at least 1 agent in 3 or more antibiotic agents. Extensively drug-resistant (XDR) A. Bowman was characterized as demonstrating nonsusceptibility to at least 1 agent in all but 2 or fewer antimicrobial classes. The genes encoding aminoglycoside modifying enzymes may be located on transposons, plasmids or class 1 integrons in MDR A. baumannii strains in Europe (12-14). These genes include nucleotide transferases (aadB), AN1 (3')-Ia (aadA1), phosphotransferases (aphA6), and acetyltansferases (aacCI), which were detected by PCR and sequencing.

2. Methods

2.1. Bacterial Isolation

In this study, from June 2013 to August 2014, 100 strains of A. baumannii were collected by sterile swabs from burn patients who referred to Shahid Motahari hospital (level I burn center) in Tehran, Iran. The wound exudates were collected by swabbing and transported to Department of Medical Microbiology. A questionnaire was designed and coded for each patient. The samples were taken from burn patients included skin ulcer, blood, urine, catheter, and isolated samples from the burned area and the respiratory tract. In the laboratory, clinical samples were cultured on blood agar, MacConkey agar, and Nutrient media (Merck, Germany). After 24 hours, the coccobacillus gram-negative Acinetobacter was confirmed by Gram stain microscopy method. Isolates were characterized and confirmed in the laboratories of the corresponding hospitals through routine microbiological and biochemical tests such as citrate, moving, oxidase tests, and growth at 42°C. The confirmed samples were kept in 30% glycerol at -70°C.

2.2. Antibiotic Susceptibility Testing

Antibiotic susceptibility testing was performed according to instructions of CLSI using the following antibiotics: Piperacillin - tazobactam (10/100 µg), Cipropoloxin (5 µg), Amikacin (30 µg), Trimethoprim-sulfamethoxazole (25 µg), Tobramycin (10 µg), Ceftazidime (30 µg), Ampicillin (10 µg), Imipenem (10 µg), Meropenem (10 µg), Cefotaxime (30 µg), Cefepime (30 µg), Ceftriaxone (30 µg), Tetracycline (10 µg), Gentamicin (10 µg), and Colistin (CO10 µg) (MAST, UK) (15).

A. baumannii ATCC19606 was used as the control strain, and Escherichia coli ATCC 25922 and 352 and Pseudomonas aeruginosa ATCC 27853 were used as negative controls, moreover, the confirmed strains were used as positive and negative controls for the PCR detection of AME genes.

2.3. DNA Extraction

Genomic DNA was extracted by standard DNA Extraction Kit (Bioneer, Republic of Korea) according to the previous reports (16).

2.4. PCR and Detection of Aminoglycoside-Resistance Genes

All target genes and corresponding primers used for PCR amplification are listed in Table 1. The PCR mixture contained the forward/reverse primers, DNA template, and master mix (10 Mm of Tris-HCL, 30 Mm of KCL: 10 Mm, 30 Mm, Bioneer Company, Korea, Cat. number K-2016).

Table 1. The Sequences of Reverse and Forward Primers Used in This Study

| Primer | Primer Sequences | Product Size, bp | Annealing Temperature, °C |
|--------|-----------------|-----------------|--------------------------|
| aadB F | ATGGACACAATGGGACATGCCGGTTGCC | 495 | 55 |
| aadB R | TTAGGGCCGATAATGGGACCC | 624 | 52 |
| aadA1 F | ATGAGGGAAAGGGGTATCG | 399 | 55 |
| aadA1 R | TAAATTGGGACTCTGGTGGT | 465 | 52 |
| aphA6 F | AGCCGAAATATGTAGTGGGCT | 408 |
| aphA6 R | TCCGGTATGCTGCTAGA | 510 |
| aacCI F | ATGGGCCGCATATCGCGACC | 550 |
| aacCI R | TTAGGGCCGACTTGGGTC | 520 |

PCR conditions are illustrated in Table 2 that included 35 cycles of amplification under the following conditions: denaturation at 95°C for 3 minutes; annealing at 52 - 55°C for 1 second; and cycling was followed by 45 seconds for extension at 72°C, with a final extension at 72°C for 5 minutes. The PCR purification kit was used and sequencing was conducted by the Bioneer company. Chromas 1.45 software and BLAST were used to analyze the nucleotide sequences. We investigated genes encoding aminoglycoside resistance including aacCI that confers gentamicin resistance; aadA1 that confers tobramycin, streptomycin and spectinomycin resistance; aadB that confers tobramycin, gentamicin and kanamycin resistance; and aphA6 that confers neomycin, kanamycin, amikacin and gentamicin resistance.
Table 2. Antimicrobial Resistance Pattern of A. baumannii Against Different Antibiotics

| Antibiotic | Susceptible | Resistant | Intermediate |
|------------|-------------|-----------|--------------|
| PTZ        | 0           | 99 (99)   | 1 (1)        |
| CRO        | 0           | 100 (100) | 0            |
| CAZ        | 0           | 100 (100) | 0            |
| CTX        | 0           | 100 (100) | 0            |
| CPM        | 0           | 100 (100) | 0            |
| CIP        | 0           | 100 (100) | 0            |
| IMI        | 0           | 98 (98)   | 2 (2)        |
| MEM        | 1 (1)       | 98 (98)   | 1 (1)        |
| GEM        | 5 (5)       | 93 (93)   | 2 (2)        |
| AMK        | 5 (5)       | 90 (90)   | 5 (5)        |
| TET        | 10 (10)     | 82 (82)   | 8 (8)        |
| SXT        | 4 (4)       | 94 (94)   | 2 (2)        |
| PRL        | 0           | 100 (100) | 0            |
| TOB        | 7 (7)       | 87 (87)   | 6 (6)        |
| COL        | 100 (100)   | 0         | 0            |

Abbreviations: AMK, Amikacin; CAZ, ceftazidime; CIP, Ciprofloxacin; COL, Colistin; CPM, cefepime; CRO ceftriaxone; DOX, doxycycline; GEM, gentamicin; IPM, imipenem; MEM, meropenem; MIN, minocycline; PRL, piperacillin; PTZ, piperacillin-tazobactam; SAM, ampicillin-sulbactam; SXT, Trimethoprim-sulfamethoxazole; TET, tetracycline; TOB, tobramycin.

*Values are expressed as No. (%).

2.5. Statistical Analysis

This was a descriptive study. MINITAB16 software was used to analyze the results, with the confidence interval of 95%, and P value less than 0.05.

3. Results

3.1. The Study Population

Of the 100 burn cases, 58 (58%) were male and 42 (42%) female. The age of the burn patients ranged from 2 to 90 years, with the maximum number of cases in the age group of 41 to 60 years (n = 52).

3.2. Antibiotic Susceptibility Testing

From June 2013 to August 2014, 100 Acinetobacter strains that were recovered from burn patients at the Shahid Motahari hospital were used for this study. These isolates were collected from different places of the body including the urine (12%), sputum (3%), blood (20%), the catheter (25%), and wound (40%), respectively (Table 2). The results revealed that all strains were (100%) resistant to ceftriaxone, ciprofloxacin, cefotaxime, and (0%) colistin (Table 2). In this study, 94 strains collected from Shahid Motahhari hospital in Tehran were found to possess multidrug resistance (MDR). Screening of AME genes by PCR technique revealed that frequency of aphA6, aadB, aacC1, and aadA1 genes were 65%, 72%, 21%, and 37%, respectively. Moreover, 28 strains did not have any aminoglycoside modifying gene. Eight isolates had aadB and aphA6 genes and 3 isolates had aadB, aadA1, aacC1, and aphA6 genes. The purification of PCR products were done by tge PCR purification kit (Bioneer Co., Korea), and sequencing was done by the Bioneer company. Chi-square test was used for data analysis. A significant correlation was found between resistance to aminoglycosides and studied genes (P < 0.05); 65% of the isolates contained the phosphotransferase gene aphA6, which confers to amikacin, gentamicin, kanamycin, and neomycin resistance, 21% of isolates contained acetyltransferase genes aacC1 that confers to gentamicin resistance, and 37% contained adenyllyltransferase genes aadA1 as streptomycin, tobramycin, and spectinomycin resistance, and 72% of the isolates contained aadB that confers resistance to tobramycin, gentamicin, and kanamycin.

4. Discussion

A. baumannii is an opportunistic pathogen primarily associated with nosocomial infections worldwide (17). In addition to causing broad range of infections (eg, pneumonia, urinary tract, bloodstream, and skin infections), this organism is responsible for 10% of all nosocomial infections. Due to the formation of multi-resistant A. baumannii strains and its rapid spread, it is highly difficult to treat the infections caused the bacteria these days. Currently, the bacteria are considered as factors of mortality among hospitalized patients in hospital wards (18). Several sudden outbreaks of the bacteria are reported annually from hospitals around the world, indicating the importance of the bacteria and the need for a suitable plan to prevent infection, particularly by resistant strains. Many studies conducted in hospitals during the sudden outbreaks, revealed that hospital environments had been the source of infection in most cases (19). Various studies showed that Acinetobacter could survive for 16 weeks on dry surfaces of an environment; and this is considered as an alarm for its treatment because the isolates of A. baumannii could be isolated repeatedly from all various surfaces, indicating its high adaptability to incompatible environmental conditions. Studies have demonstrated that the survival rate of the strains isolated from dry places was higher than the ones isolated form humid places, and thus having a higher potential to cause nosocomial outbreaks (20).
antibiotic susceptibility testing of strains show that nosocomial strains have a higher antibiotic resistance, which increases the chances of survival of the bacteria in environments such as ICU, where patients consume broad-spectrum antibiotics such as carbapenems (21). This will lead to an increased risk of colonization and infection of patients. Aminoglycosides have been an essential group of antibacterial agents used in the treatment of genuine bacterial diseases, particularly those with aerobic gram-negative bacteria. However, recent studies demonstrated the development of resistance to aminoglycosides in Acinetobacter isolates in various parts of the world. Resistance to aminoglycosides in Acinetobacter is mainly due to the inactivation of the antimicrobials by particular modifying enzymes such as adenylyltransferases, phosphotransferases, and acetyl transferases (22, 23). In a study done by Facile et al. in Iran, colistin resistance rate was 11.6%, and 95% of isolates were considered as MDR isolates. However, in the current study, antibiotic resistance patterns showed that 11.6% of strains were MDR isolates. In this study, the rate of resistance to imipenem and meropenem was 98% and to ciprofloxacin and colistin was 100% (24). Akers et al. in a survey conducted in Texas, determined the susceptibility to ciprofloxacin and colistin was 100% (24). Also, Aliakbarzade et al. in their investigation in 2013, similar to the current study, found that the highest rate of resistance was related to colistin (77%). Also, they reported that the frequency of, aadB, aphA6, aacCI, and aadA1 and genes among 103 Acinetobacter strains was 18.6%, 27.9%, 60.46%, and 65.11%, respectively. In their study, the rate of resistance to aminoglycosides and frequency of AME genes was less than that of our survey (14). According to the current study, the most effective antimicrobial agent against MDR A. baumannii isolates is colistin. Although it seems that this antibacterial agent has a great influence on this opportunistic pathogen, it has a serious side effect in the host. Therefore, it should only be used as the last choice drug.

In almost all the mentioned studies, Acinetobacter resistance to aminoglycosides was less than our study, indicating an increase in resistance to antibiotics in this bacterium. Aminoglycosides resistance in Acinetobacter has emerged as an important health problem. Our results revealed that clinical isolates of the bacteria in burn patients carry different types of genes encoding aminoglycoside-modifying enzymes and should be managed by timely detection and exact isolation methods to help diminish their severe sequel and mortality rate of the patients.

Acknowledgments

We would like to thank the personnel of cellular and molecular biology research center and microbiology department of Shahid Beheshti University of Medical Sciences for their cooperation.

Footnotes

Authors’ Contribution: All the authors cooperated in conducting the isolation, performing the experimental work, as well as in writing the manuscript.

Funding/Support: This study was supported by a fund provided by Cellular and molecular biology research center (grant NO: 5074) (Code of ethics: IR.SBMU.RAM.REC.1394.80).

References

1. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev. 2006;19(2):403–34. doi: 10.1128/CMR.19.2.403-434.2006. [PubMed: 16642555].

2. Al-Aali KY. Microbial Profile of Burn Wound Infections in Burn Patients, Taif, Saudi Arabia. Arch Clin Microbiol. 2016.

3. Nemec A, Dolzani L, Brisse S, van den Broek P, Dijkshoorn L. Diversity of aminoglycoside-resistance genes and their association with class 1 integrons among strains of pan-European Acinetobacter baumannii clones. J Med Microbiol. 2004;53(Pt 12):233–40. doi: 10.1099/jmm.0.45716-0. [PubMed: 15585503].

4. Goudarzi H, Hashemi S, Fatemeh F, Noori M, Erfanimanesh S, Yosef N, et al. Detection of blaDIM, blaim, bladm, bladm and blavm genes among Acinetobacter baumannii strains isolated from hospitalized patients in Tehran hospitals, Iran. Iran J Med Microbiol. 2006;9(4):32–9.

5. Heidary M, Hashemi A, Goudarzi H, Khoshnood S, Roshani M, Azimi H, et al. The antibacterial activity of Iranian plants extracts against metallo-beta-lactamase producing Pseudomonas aeruginosa strains. J Paramed Sci. 2016;7(1):113–9.

6. Guide AA. Guide to the Elimination of Multidrug-resistant Acinetobacter baumannii Transmission in Healthcare Settings. ; 2014.
7. Mozes J, Ebrahimi F, Goracz O, Misztu C, Kardos G. Effect of carbapenem consumption patterns on the molecular epidemiology and carbapenem resistance of Acinetobacter baumannii. J Med Microbiol. 2014;63(12):1654-62. doi: 10.1099/jmm.0.082818-0. [PubMed: 2528664].

8. Coyne S, Courvalin P, Galimand M. Acquisition of multidrug resistance transposon Tn6061 and IS6000-mediated large chromosomal inversions in Pseudomonas aeruginosa clinical isolates. Microbiol. 2010;156(5):1448-58. doi: 10.1099/mic.0.033639-0. [PubMed: 2080024].

9. Zhao SY, Jiang DY, Xu PC, Zhang YK, Shi HF, Cao HL, et al. Investigation of multidrug-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2014;69(1):7-15. doi: 10.1093/jac/dkt280. [PubMed: 24888195].

10. Roshani M, Heidary M, Goudarzi H, Hashemi A, Eslami G, Yousefi N. Investigation of drug-resistant Acinetobacter baumannii infections in a comprehensive hospital of East China. Ann Clin Microbiol Antimicrob. 2015;14(7):1504-9. doi: 10.1093/jac/dkr163. [PubMed: 21586593].

11. Koczura R, Przyszłakowsa B, Kaznowski A. Characterization of carbapenem-resistant Acinetobacter baumannii Strains Isolated from Inpatients. Balkan Med J. 2015;32(1):79-83. doi: 10.3152/balkanmedj.2015.3202. [PubMed: 25759776].

12. Turton JF, Kaufmann ME, Glover J, Coelho JM, Warner M, Pike R, et al. Detection of aac(6′)-Ib-cr, and qepA genes among clinical isolates of Escherichia coli and Klebsiella pneumoniae. Acta microbiologica et immunologica Hungarica. 2016;64(1):63-9.

13. Chang Y, Luan G, Xu Y, Wang Y, Shen M, Zhang C, et al. Characterization of carbapenem-resistant Acinetobacter baumannii isolates in a Chinese teaching hospital. Front Microbiol. 2015;6: doi: 10.3389/fmicb.2015.00910.

14. Heidary M, Salimi Chirani A, Khoshnood S, Eslami G, Ayatabi SM, Nazem H, et al. Molecular detection of aminoglycoside-modifying enzyme genes in Acinetobacter baumannii clinical isolates. Acta microbiologica et immunologica Hungarica. 2016;63(1):8.

15. CLSI. Performance standard for antimicrobial susceptibility testing; seventeenth informational supplement, M100_S17. Wayne: Clinical and Laboratory Standards Institute; 2015.

16. Heidary M, Bahramian A, Hashemi A, Goudarzi M, Omrani VF, Eslami G, et al. Detection of actA, acrB, aac(6′)-Ib-cr, and qepA genes among clinical isolates of Acinetobacter baumannii producing the OXA-23 beta-lactamase in Korea. J Clin Microbiol. 2005;43(5):2241-5. doi: 10.1128/JCM.43.5.2241-2245.2005. [PubMed: 15872249].

17. Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21(3):538-82. doi: 10.1128/CMR.00058-07. [PubMed: 18625687].

18. Montefour K, Frieden J, Hurst S, Helmich C, Headley D, Martin M, et al. Acinetobacter baumannii: an emerging multidrug-resistant pathogen in critical care. Crit Care Nurse. 2008;28(3):135-55. [PubMed: 18238934].

19. Fournier PE, Richet H, Weinstein RA. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006;42(5):692-9.

20. Vakili B, Fazeli H, Shoaei P, Yaran M, Ataei B, Khorvash F, et al. Detection of colistin sensitivity in clinical isolates of Acinetobacter baumannii in Iran. Official J Isfahan Univ Med Sci. 2014;20(Suppl 1):S567-9.

21. Montefour K, Frieden J, Hurst S, Helmich C, Headley D, Martin M, et al. Acinetobacter baumannii: an emerging multidrug-resistant pathogen in critical care. Crit Care Nurse. 2008;28(3):135-55. [PubMed: 18238934].

22. Aksoy MD, Cavuslu S, Tugrul HM. Investigation of Metallo Beta Lactamases and Oxacillinases in Carbapenem Resistant Acinetobacter baumannii Strains Isolated from Inpatients. Balkan Med J. 2015;32(1):79-83. doi: 10.3152/balkanmedj.2015.3202. [PubMed: 25759776].

23. Fournier PE, Richet H, Weinstein RA. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006;42(5):692-9.

24. Vakili B, Fazeli H, Shoaei P, Yaran M, Ataei B, Khorvash F, et al. Detection of colistin sensitivity in clinical isolates of Acinetobacter baumannii in Iran. Official J Isfahan Univ Med Sci. 2014;20(Suppl 1):S567-9.

25. Akers CH, Chaney C, Barsoumian A, Beckius M, Zera W, Yu X, et al. Aminoglycoside resistance and susceptibility testing errors in Acinetobacter baumannii-calcoaceticus complex. J Clin Microbiol. 2010;48(4):1132-8. doi: 10.1128/JCM.02006-09. [PubMed: 20070879].

26. Shakhbaie MR, Adeli S, Salehi MH. Antibiotic resistance patterns and extended-spectrum beta-lactamase production among Acinetobacter spp. isolated from an intensive care Unit of a hospital in Kerman, Iran. Antimicrob Resist Infect Control. 2012;1(1):3. doi: 10.1186/2047-2994-1-1. [PubMed: 22958725].